BEAM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
490.0K
-98.5%
31.7M
-72.2%
114.1M
+1076.6%
9.7M
+14.6%
8.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
490.0K
-98.5%
31.7M
-72.2%
114.1M
+1076.6%
9.7M
+14.6%
8.5M
Operating Expenses
127.2M
-8.4%
139.0M
+5.6%
131.6M
-3.6%
136.5M
+6.1%
128.6M
R&D
95.1M
-9.0%
104.5M
+5.3%
99.3M
-9.6%
109.8M
+7.9%
101.8M
SG&A
31.9M
-7.2%
34.4M
+6.7%
32.3M
+20.7%
26.7M
-0.4%
26.9M
Operating Income
-126758000
-18.2%
-107215000
-514.6%
-17445000
+86.2%
-126811000
-5.5%
-120179000
EBITDA
-121348000
-19.4%
-101610000
-762.8%
-11777000
+90.3%
-121251000
-5.8%
-114641000
Net Income
-122678000
-30.1%
-94318000
-138.6%
244.3M
+316.7%
-112728000
-10.4%
-102138000
EPS (Basic)
$-1.18
-29.7%
$-0.91
-138.4%
$2.37
+315.5%
$-1.10
-10.0%
$-1.00
EPS (Diluted)
$-1.18
-29.7%
$-0.91
-138.4%
$2.37
+315.5%
$-1.10
-10.0%
$-1.00
Shares (Diluted)
104.3M
+1.0%
103.3M
+0.2%
103.1M
+0.5%
102.6M
+0.6%
102.0M
Beam Therapeutics (BEAM) โ€” Financials